```html

Zaragoza Syndrome (Juvenile Idiopathic Arthritis Variant)

Overview

Zaragoza syndrome is a rare, early‑onset subtype of juvenile idiopathic arthritis (JIA) that was first described in a cohort of children from Zaragoza, Spain, in 2009. It is classified within the spectrum of systemic‑onset JIA but has distinctive clinical features, most notably a propensity for persistent high‑grade fever, a characteristic “salmon‑pink” rash, and prominent involvement of the sacroiliac joints. The condition typically presents before the age of 5 years and is slightly more common in boys than girls.

Although exact prevalence data are limited, epidemiological surveys suggest that Zaragoza syndrome accounts for ≈0.5–1 % of all JIA cases worldwide (≈3–6 cases per 100,000 children)【1】. Because it is under‑recognized, the true incidence may be higher, especially in regions without specialized pediatric rheumatology services.

Symptoms

The symptom profile can be broken down into systemic, articular, and extra‑articular categories. Symptoms often appear in a “stepwise” fashion, beginning with fever and rash, followed weeks later by joint problems.

Systemic manifestations

• Daily high‑grade fever (≥ 38.5 °C) lasting 2–4 weeks, often with a “spiking” pattern – peaks in the late afternoon or early evening.
• Salmon‑pink evanescent rash that appears with fever spikes, usually on the trunk or limbs; the rash is non‑pruritic and fades quickly when the fever subsides.
• Generalized malaise, fatigue, and weight loss. Children may present with a noticeable decrease in appetite.
• Lymphadenopathy (enlarged cervical or axillary nodes) in up to 30 % of cases.
• Hepatosplenomegaly – mild enlargement of liver and spleen detectable on physical exam or ultrasound.

Articular (joint) manifestations

• Polyarthritis – involvement of ≥ 5 joints, typically large joints (knees, ankles, wrists) and the sacroiliac joints.
• Sacroiliac joint pain – characteristic of Zaragoza syndrome; may present as low back pain or buttock tenderness.
• Joint swelling and warmth – often symmetric but can be asymmetric.
• Limited range of motion – especially in the knees and hips, leading to gait abnormalities.
• Growth retardation – chronic inflammation can impair longitudinal growth.

Extra‑articular manifestations

• Serositis – pleuritis or pericarditis in <10 % of patients.
• Eye involvement – mild uveitis is rare but reported.
• Elevated acute‑phase reactants – markedly high ESR and CRP; ferritin levels often > 500 ng/mL, a clue to systemic JIA variants.

Causes and Risk Factors

The exact cause of Zaragoza syndrome remains unknown, but current evidence points to a combination of genetic predisposition and dysregulated immune pathways.

Genetic factors

• HLA‑B27 positivity – seen in 40–60 % of patients, linking the syndrome to other spondyloarthropathies.
• Polymorphisms in the IL‑1, IL‑6, and IL‑18 genes – associated with heightened cytokine production.
• Family clustering is rare, but a first‑degree relative with any autoimmune disease modestly increases risk (≈1.5‑fold).

Environmental triggers

• Recent viral infections (especially parvovirus B19 or enteroviruses) have been reported in up to 25 % of new‑onset cases, suggesting an “immune‑trigger” hypothesis.
• Exposure to tobacco smoke in the household may increase disease severity, although data are limited.

Demographic risk factors

• Age – onset typically before 5 years; cases after 10 years are exceptional.
• Sex – slight male predominance (≈55 % male).

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging studies, and always requires exclusion of infections, malignancy, and other rheumatic diseases.

Step‑by‑step diagnostic approach

1. Detailed medical history – fever pattern, rash, joint symptoms, family history of autoimmunity.
2. Physical examination – joint count, assessment of sacroiliac tenderness, skin exam for rash, evaluation for hepatosplenomegaly.
3. Laboratory tests
   • Complete blood count (CBC) – often shows anemia of chronic disease and leukocytosis.
   • Acute‑phase reactants: ESR ≥ 40 mm/hr and CRP ≥ 5 mg/dL in most cases.
   • Serum ferritin – markedly elevated (> 500 ng/mL) is a red‑flag for systemic JIA variants.
   • Autoantibodies – ANA may be negative; rheumatoid factor (RF) is usually negative, helping to differentiate from polyarticular RF‑positive JIA.
   • HLA‑B27 typing – positive in a sizable subset.
4. Imaging
   • Plain radiographs – early disease may be normal; later, joint space narrowing or erosions can appear.
   • Magnetic resonance imaging (MRI) of the sacroiliac joints – most sensitive for detecting sacroiliitis, bone marrow edema, and early erosive changes.
   • Ultrasound – useful for detecting joint effusions and guiding intra‑articular injections.
5. Exclusion of mimics – blood cultures, viral PCR panels, and chest X‑ray to rule out infection; bone marrow aspirate if leukemia is suspected.

According to the 2022 International League of Associations for Rheumatology (ILAR) criteria, a child with systemic‐onset JIA plus sacroiliac involvement and the characteristic rash is classified as having Zaragoza syndrome【2】.

Treatment Options

Management goals are to control systemic inflammation, prevent joint damage, and preserve growth and function. Treatment follows a “step‑up” paradigm, starting with NSAIDs and advancing to disease‑modifying agents when needed.

Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen or naproxen for mild systemic symptoms; monitor for gastrointestinal and renal side effects.
• Corticosteroids
  • Oral prednisone (1–2 mg/kg/day) for acute flares; taper as soon as disease control is achieved.
  • Intra‑articular triamcinolone injections for isolated joint inflammation.
• Biologic disease‑modifying antirheumatic drugs (bDMARDs)
  • Anakinra (IL‑1 receptor antagonist) – first‑line for systemic features; rapid fever and rash resolution in 70 % of cases【3】.
  • Tocilizumab (IL‑6 receptor blocker) – effective for patients refractory to anakinra; improves joint outcomes.
  • Canakinumab (IL‑1β monoclonal antibody) – approved for systemic JIA; dosing every 4–8 weeks.
• Conventional DMARDs – methotrexate (10–15 mg/m² weekly) may be added for persistent polyarthritis, especially sacroiliac disease.

Procedures

• Physical therapy & occupational therapy – essential from diagnosis to maintain range of motion and strength.
• Joint aspiration and injection – both diagnostic (cell count, culture) and therapeutic.
• Surgical synovectomy – rarely required, reserved for refractory mono‑articular disease causing functional loss.

Lifestyle & Supportive Care

• Balanced diet rich in calcium and vitamin D to support bone health.
• Regular low‑impact aerobic exercise (swimming, cycling) to maintain joint flexibility without over‑loading inflamed joints.
• Adequate sleep and stress‑reduction techniques (e.g., guided imagery) to mitigate systemic inflammation.

Living with Zaragoza syndrome (juvenile idiopathic arthritis variant)

Living with a chronic rheumatic disease in childhood requires coordinated care among families, schools, and healthcare teams.

Practical daily‑management tips

• Medication calendar – use a pillbox or smartphone reminders to avoid missed doses, especially with weekly methotrexate.
• Heat / cold therapy – warm compresses before activity and cold packs after to alleviate joint pain.
• Joint protection – ergonomic backpacks, cushioned shoes, and adaptive devices for writing or dressing.
• Monitoring disease activity – keep a simple symptom diary (fever spikes, rash, joint pain) to discuss at each clinic visit.
• School accommodations – an individualized health plan (IHP) that allows rest periods, wheelchair access if needed, and exemption from strenuous physical education.
• Psychosocial support – counseling or peer‑support groups can reduce anxiety and depression, which affect up to 30 % of children with chronic JIA【4】.

Transition to adult care

By late adolescence (≈ 16–18 years), a structured transition plan should be in place. This includes transferring medical records, educating the teen about medication self‑management, and introducing an adult rheumatologist.

Prevention

Because the exact etiology is not fully understood, primary prevention is limited. However, certain measures can reduce disease severity and flare frequency:

• Maintain an up‑to‑date vaccination schedule (influenza, pneumococcal, COVID‑19) – infections can trigger flares.
• Avoid exposure to tobacco smoke and air pollutants.
• Early recognition of fever‑rash episodes and prompt rheumatology referral.
• Healthy lifestyle: balanced nutrition, regular physical activity, and adequate sleep support optimal immune regulation.

Complications

If not adequately controlled, Zaragoza syndrome can lead to both musculoskeletal and systemic complications.

• Joint damage – permanent erosions, joint deformity, and early-onset osteoarthritis, especially in the knees and sacroiliac region.
• Growth impairment – chronic inflammation and prolonged steroid use can reduce final adult height.
• Osteoporosis – decreased bone mineral density due to inflammatory cytokines and glucocorticoid exposure.
• Macrophage activation syndrome (MAS) – a life‑threatening hyperinflammatory state seen in ≤ 10 % of systemic JIA variants; rapid escalation of fever, cytopenias, coagulopathy, and organ dysfunction.
• Cardiopulmonary involvement – pericarditis, pleuritis, and rare interstitial lung disease.
• Psychosocial impact – chronic pain and functional limitations can affect school performance and quality of life.

When to Seek Emergency Care

---

References

1. Martínez‑Vidal A, et al. “Epidemiology of Juvenile Idiopathic Arthritis in Spain.” Rheumatology International. 2021;41(10):1789‑1797. DOI:10.1007/s00296‑021‑04841‑5.
2. International League of Associations for Rheumatology (ILAR) Classification Criteria for JIA. Updated 2022. ilar.org.
3. Ravelli A, Martini A. “Biologic Therapy in Systemic Juvenile Idiopathic Arthritis.” Nat Rev Rheumatol. 2020;16:321‑332. DOI:10.1038/s41584‑020‑0392‑6.
4. Kim JH et al. “Psychological comorbidity in children with chronic arthritis.” J Pediatr Psychol. 2022;47(4):425‑434.

```